Letters to the Editor
5 November 2024
Vol. 2 No. 3 (2024)
Mavacamten’s therapeutic impact: cardiac-specific myosin inhibition in obstructive hypertrophic cardiomyopathy
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
2220
Views
542
Downloads
0
HTML
Authors
Dear Editor,
Obstructive hypertrophic cardiomyopathy (oHCM) is a hereditary cardiac condition, affecting 1 in about 500 individuals, characterized by an atypical thickening of the heart muscle, specifically the interventricular septum...
Altmetrics
Downloads
Download data is not yet available.
Citations
Geske JB, Ommen SR, Gersh BJ. Hypertrophic cardiomyopathy: clinical update. JACC Heart Fail 2018;6:364-375. DOI: https://doi.org/10.1016/j.jchf.2018.02.010
Braunwald E, Saberi S, Abraham TP, Elliott PM, Olivotto I. Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy. Eur Heart J 2023;44:4622-33. DOI: https://doi.org/10.1093/eurheartj/ehad637
Zampieri M, Argirò A, Marchi A, et al. Mavacamten, a novel therapeutic strategy for obstructive hypertrophic cardiomyopathy. Curr Cardiol Rep 2021;23:79. DOI: https://doi.org/10.1007/s11886-021-01508-0
Makhija M, Bansal A, Jakhar P, Sharma L, Kumar S, Gupta D. Mavacamten: a novel avenue towards hypertrophic obstructive cardiomyopathy. Int J Basic Clin Pharmacol 2024;13:568-72. DOI: https://doi.org/10.18203/2319-2003.ijbcp20241661
Yacoub MS, El-Nakhal T, Hasabo EA, et al. A systematic review and meta-analysis of the efficacy and safety of Mavacamten therapy in international cohort of 524 patients with hypertrophic cardiomyopathy. Heart Fail Rev 2024;29:479-96. DOI: https://doi.org/10.1007/s10741-023-10375-6
Hegde SM, Lester SJ, Solomon SD, et al. Effect of mavacamten on echocardiographic features in symptomatic patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2021;78:2518-32. DOI: https://doi.org/10.1016/j.jacc.2021.09.1381
How to Cite
1.
Shabbir A, Yumn L, Khan E. Mavacamten’s therapeutic impact: cardiac-specific myosin inhibition in obstructive hypertrophic cardiomyopathy. Global Cardiol [Internet]. 2024 Nov. 5 [cited 2025 Aug. 12];2(3). Available from: https://www.globalcardiology.info/site/article/view/48
Copyright (c) 2024 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Similar Articles
- Shiva Seyed Mokhtassi, Nika Majidi, Yousuf Salmasi, Akhil Sonecha, Sanjay Agrawal, Mubassher Husain, Diana Garcia, Jerry Mitchell, Espeed Khoshbin, How organ care system saved the day during a donation after circulatory death heart transplant: a case of complicated sternal re-entry , Global Cardiology: Vol. 3 No. 1 (2025)
- Laibah Arshad Khan, Muhammad Shahzeb Khan, Rania Usman Latif, Markus S. Anker, Cardiac wasting in patients with advanced cancer: state of the art review , Global Cardiology: Vol. 3 No. 1 (2025)
- Muhammad Shahzeb Khan, Javed Butler, Tim Friede, Piotr Ponikowski, Stefan D. Anker, To clip or not to clip moderate-to-severe functional mitral regurgitation in patients with heart failure? , Global Cardiology: Vol. 2 No. 3 (2024)
- Ali A. Youssef, Shaima Al-Omani, Mustafa A. Alrefae, Ahmad Suliman, Reem Hassan, Omar Saleh, Zizi S. Khalifa, New left ventricular thrombus and embolic events in left ventricular dysfunction postmyocardial infarction , Global Cardiology: Vol. 2 No. 3 (2024)
- Anders Larsson, Bertil Wegmann, Toralph Ruge, Joakim Alfredsson, Carl Johan Östgren, Tomas Lindahl, Elevated endostatin is associated with hypertension treatment, elevated high sensitivity C-reactive protein, increased waist-hip ratio, and attenuated kidney function, but not with age, in a middle-aged population , Global Cardiology: Vol. 3 No. 1 (2025)
- Stefan D. Anker, Javed Butler, Khawaja M. Talha, Tim Friede, Using multiple primary endpoints in clinical trials with a focus on heart failure , Global Cardiology: Vol. 2 No. 2 (2024)
- Stefan D. Anker, Muhammad Shahzeb Khan, Laibah Arshad Khan, Giuseppe M.C. Rosano, Maurizio Volterrani, Mitja Lainscak, Piotr Ponikowski, Andrew J.S. Coats, The muscle hypothesis of shortness of breath in patients with cachexia , Global Cardiology: Vol. 2 No. 4 (2024)
- Muhammad Usman Almani, Jafar Alzubi, Muhammad Yousuf, Razan Alrawashdeh, Noor Fatima, Mohammad Al Madani, Raphael Bonita, Pulmonary artery pressure sensor device performance in patients with atrial fibrillation/flutter , Global Cardiology: Vol. 2 No. 4 (2024)
- Arif Albulushi, Lama S. Alfehaid, Mosaad Alhussein, Amr Youssef, Evaluating serum galectin-3 binding protein as a diagnostic and prognostic biomarker in pulmonary arterial hypertension: a comparative study , Global Cardiology: Vol. 2 No. 4 (2024)
- Elias Tassoulas, Dimitrios Tasoulas, Christos Papaconstantinou, Ioannis Chlorogiannis, Prognostic factors and outcome in patients submitted into coronary artery bypass surgery with total arterial myocardial revascularization , Global Cardiology: Vol. 2 No. 4 (2024)
You may also start an advanced similarity search for this article.
